Why Dyne Therapeutics Stock Was a Big Winner on Wednesday
Summarize this article with:
By Eric Volkman – Dec 10, 2025 at 6:00PMKey PointsAn analyst upgraded his recommendation on the biotech.He now feels it's worthy of a buy, and what's more, he almost quadrupled his price target.These 10 Stocks Could Mint the Next Wave of Millionaires ›NASDAQ: DYNDyne TherapeuticsMarket Cap$2.6BToday's Changeangle-down(6.78%) $1.25Current Price$19.69Price as of December 10, 2025 at 4:00 PM ETThe company is attracting much investor attention this week because of what happened in the lab.Dyne Therapeutics (DYN +6.78%) stock stood apart from its biotech peers on Hump Day, posting a meaty share price gain across the trading session. On the back of an analyst's upgrade, accompanied by a significant price target raise, investors piled into the stock to lift it to a nearly 7% increase. A new bull in the pen The person behind the upgrade was Jay Olson of Oppenheimer. Before market open, he changed his recommendation on Dyne stock to outperform (buy, in other words) from his previous perform (hold). He also nearly quadrupled his price target on the shares, to $40 apiece from $11. Image source: Getty Images. The exact reasoning for his move wasn't exactly clear. It doesn't seem coincidental that it came shortly after Dyne's latest report from the laboratory. On Monday, the company published a readout from a phase 1/2 clinical trial of its Duchenne muscular dystrophy (DMD) investigational drug zeleciment rostudirsen, which achieved both its primary and secondary endpoints. Zeleciment rostudirsen was found to be efficacious in bolstering the production of a structural protein called dystrophin, which serves to protect muscles. ExpandNASDAQ: DYNDyne TherapeuticsToday's Change(6.78%) $1.25Current Price$19.69Key Data PointsMarket Cap$3BDay's Range$19.25 - $20.6052wk Range$6.36 - $28.96Volume10MAvg Vol2.8MGross Margin0.00%Dividend YieldN/A Big movements Dyne is clearly eager to push the pipeline drug through the development process; it stated that it aims to submit it for accelerated U.S. Food and Drug Administration (FDA) approval in the second quarter of 2026 -- mere months away.Advertisement The company's stock has been a bit of a rollercoaster this week, with initial investor optimism souring on Tuesday after the company announced a relatively large secondary stock offering. I'd be bouncing along with the bulls, myself, as those trial results were impressive and suggest zeleciment rostudirsen might have a bright future when and if it hits pharmacy shelves.About the AuthorEric Volkman is a contributing Motley Fool finance and stock market analyst. Previously, Eric was an equities analyst at European investment bank Raiffeisen Capital and Investment. He’s also been a freelance finance writer since 1995. He studied at Susquehanna University.TMFVolkmanRead NextDec 9, 2025 •By Eric VolkmanWhy Dyne Therapeutics Stock Tanked on TuesdayDec 8, 2025 •By Eric VolkmanWhy Dyne Therapeutics Stock Was Blasting Higher TodayNov 21, 2025 •By Eric VolkmanWhy Dyne Therapeutics Stock Was Crushing it This WeekOct 27, 2025 •By Eric VolkmanWhy Dyne Therapeutics Stock Crushed the Market on MondaySep 15, 2023 •By James HalleyWhy Shares of Dyne Therapeutics Fell This WeekJan 18, 2022 •By James HalleyWhy Shares of Dyne Therapeutics Dropped 18.1% on Tuesday